{"filing":{"accession_number":"0001178913-26-003438","cik":"0001498403","ticker":"BLRX","company_name":"BioLineRx Ltd.","form":"6-K","filing_date":"2026-07-08","report_date":null,"primary_document":"zk2635661.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1498403/000117891326003438/zk2635661.htm"},"events":[{"id":16592,"run_id":14824,"accession_number":"0001178913-26-003438","anchor_item_number":"EX-99","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces preclinical data demonstrating synergistic efficacy between GLIX1 and PARP inhibitors in an ovarian cancer xenograft model. The disclosure is material because it represents a significant positive development for BioLineRx's lead asset GLIX1, directly supporting the company's clinical development strategy and justifying expansion into an ovarian cancer arm of the Phase 1/2a trial. While not a discrete M\u0026A, financing, or governance event, this operational milestone—demonstrating proof-of-concept for a novel combination therapy mechanism—would affect a reasonable investor's assessment of the registrant's pipeline value and clinical prospects.","company_name":"BioLineRx Ltd.","ticker":"BLRX","filing_date":"2026-07-08","form":"6-K","submitted_at":null,"items":[{"id":14742,"accession_number":"0001178913-26-003438","item_number":"EX-99","item_title":"exhibit_1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces preclinical data demonstrating synergistic efficacy between GLIX1 and PARP inhibitors in an ovarian cancer xenograft model. The disclosure is material because it represents a significant positive development for BioLineRx's lead asset GLIX1, directly supporting the company's clinical development strategy and justifying expansion into an ovarian cancer arm of the Phase 1/2a trial. While not a discrete M\u0026A, financing, or governance event, this operational milestone—demonstrating proof-of-concept for a novel combination therapy mechanism—would affect a reasonable investor's assessment of the registrant's pipeline value and clinical prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-08T11:09:45.696272+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14742,"accession_number":"0001178913-26-003438","item_number":"EX-99","item_title":"exhibit_1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces preclinical data demonstrating synergistic efficacy between GLIX1 and PARP inhibitors in an ovarian cancer xenograft model. The disclosure is material because it represents a significant positive development for BioLineRx's lead asset GLIX1, directly supporting the company's clinical development strategy and justifying expansion into an ovarian cancer arm of the Phase 1/2a trial. While not a discrete M\u0026A, financing, or governance event, this operational milestone—demonstrating proof-of-concept for a novel combination therapy mechanism—would affect a reasonable investor's assessment of the registrant's pipeline value and clinical prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-08T11:09:45.696272+00:00","company_name":"BioLineRx Ltd.","ticker":"BLRX","filing_date":"2026-07-08"}]}